All Updates

All Updates

icon
Filter
Partnerships
Fulgent Pharma and Moffitt Cancer Center partner to advance personalized cancer therapies
Precision Medicine
May 15, 2024
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Product updates
Uber releases five new features for holiday travel season
Travel Tech
Yesterday
Precision Medicine

Precision Medicine

May 15, 2024

Fulgent Pharma and Moffitt Cancer Center partner to advance personalized cancer therapies

Partnerships

  • Fulgent Pharma has partnered with Moffitt Cancer Center to accelerate the development of personalized cancer therapies.

  • The collaboration grants Moffitt priority access to Fulgent's resources and know-how to expedite the advancement of Fulgent's clinical pipeline. This includes prioritizing clinical trials, enhancing patient screening, and data sharing. Together, the companies aim to develop personalized cancer treatments using Moffitt's scientific expertise and Fulgent's nanotherapeutic drug development platform.

  • Fulgent Pharma is a clinical-stage pharmaceutical company specializing in the development and commercialization of novel cancer therapies. The company is a subsidiary of the nanobiotechnology company Fulgent Genetics. Fulgent Pharma focuses on creating treatments through technologies such as nanoencapsulation to improve the delivery and efficacy of cancer drugs. Its pipeline includes targeted therapies for various cancers, such as breast, lung, ovarian, colon, and pancreatic.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.